drugset / Trial / NCT07108036
A Study to Assess Anktiva in Patients With Long Covid-19.
NaSingle-groupOpen-labelTreatment
Summary
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
Timeline
- Start
- 2025-11-14
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-803 | Protein / enzyme biologic | — | Subcutaneous |